<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781922</url>
  </required_header>
  <id_info>
    <org_study_id>001-CLJ-001</org_study_id>
    <nct_id>NCT02781922</nct_id>
  </id_info>
  <brief_title>Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)</brief_title>
  <acronym>APOLLON</acronym>
  <official_title>Efficacy and Safety Study of Autologous Cardiac Stem Cells (JRM-001) Treated After Reconstructive Surgery in Pediatric Patients With Congenital Heart Disease: A Multicenter Randomized Single-blind Parallel-group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Regenerative Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Regenerative Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of intracoronary injection
      of JRM-001 after reconstructive surgery in pediatric patients with functional single
      ventricle
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ejection fraction (EF(%)) assessed by MRI from baseline</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EF(%) assessed by echocardiograms from baseline</measure>
    <time_frame>Screening, Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EF(%) assessed by cardiac catheterization from baseline</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ea/Ees assessed by cardiac catheterization from baseline</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ventricular Stiffness assessed by cardiac catheterization from baseline</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart failure index from baseline</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL) index from baseline</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypoplastic Left Heart Syndrome</condition>
  <condition>Single Ventricle</condition>
  <arm_group>
    <arm_group_label>Autologous cardiac stem cells (JRM-001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous cardiac stem cells (JRM-001)</intervention_name>
    <description>3x 10^5 cells/kg, single treatment</description>
    <arm_group_label>Autologous cardiac stem cells (JRM-001)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functional single ventricle patient with heart failure who is scheduled for stage 2
             (Glenn) or stage 3 (Fontan) surgery

          -  EF(%) by echocardiography â‰¤ 55%

          -  Able to obtain written informed consent of participation in the study by a parent of
             the patient

        Exclusion Criteria:

          -  Known medical history of cardiogenic shock

          -  Lethal, uncontrollable arrhythmia

          -  Complication of coronary artery disease

          -  Eisenmenger syndrome

          -  Complication of brain dysfunction due to circulatory failure

          -  Malignant neoplasm

          -  Complication of severe neurologic disorder

          -  Severe pulmonary embolism or pulmonary hypertension

          -  Severe renal failure

          -  Multiple organ failure

          -  Active infection (including endocarditis)

          -  Sepsis

          -  Active hemorrhagic disease (e.g. gastrointestinal bleeding, injury)

          -  Known history of hypersensitivity to anti-infective drugs

          -  Inability to complete the protocol treatment and baseline to follow-up examinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideaki Ueda, M.D.</last_name>
      <phone>+81-45-711-2351</phone>
    </contact>
    <investigator>
      <last_name>Hideaki Ueda, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin-ichi Ohtsuki, M.D., Ph.D</last_name>
      <phone>+81-86-223-7151</phone>
    </contact>
    <investigator>
      <last_name>Shin-ichi Ohtsuki, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Children's Hospital</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kisaburo Sakamoto, M.D.</last_name>
      <phone>+81-54-247-6251</phone>
    </contact>
    <investigator>
      <last_name>Kisaburo Sakamoto, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015 Feb 13;116(4):653-64. doi: 10.1161/CIRCRESAHA.116.304671. Epub 2014 Nov 17.</citation>
    <PMID>25403163</PMID>
  </reference>
  <reference>
    <citation>Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, Oh H. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015 Nov;150(5):1198-1207, 1208.e1-2. doi: 10.1016/j.jtcvs.2015.06.076. Epub 2015 Jul 8.</citation>
    <PMID>26232942</PMID>
  </reference>
  <reference>
    <citation>Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, Hirai K, Fukushima Y, Baba K, Goto T, Horio N, Kobayashi J, Kuroko Y, Kotani Y, Arai S, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology: The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. Circ Res. 2017 Mar 31;120(7):1162-1173. doi: 10.1161/CIRCRESAHA.116.310253. Epub 2017 Jan 4.</citation>
    <PMID>28052915</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>September 10, 2017</last_update_submitted>
  <last_update_submitted_qc>September 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac stem/progenitor cells</keyword>
  <keyword>autologous cell therapy</keyword>
  <keyword>functional single ventricle</keyword>
  <keyword>congenital heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

